---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216744"
form_type: "8-K"
ticker: "EIKN"
cik: "0001861123"
company_name: "Eikon Therapeutics, Inc."
filed_at: "2026-05-11T20:05:32+00:00"
generated_at: "2026-05-11T22:49:23.548014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance

## Summary
- Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.
- Cash, equivalents and marketable securities $596M at March 31, 2026; expected to fund operations into H2 2027.
- EIK1001: Phase 2 NSCLC trial fully enrolled; updated data at ASCO; Phase 2/3 trials in melanoma and NSCLC initiated.
- EIK1003: Dose escalation completed; Phase 2 dose optimization trial first patient dosed; global site selection for Cohort 1D started.
- EIK1005 (WRN helicase inhibitor): Phase 1/2 trial began dosing Feb 2026; two abstracts accepted for ASCO.

## SEC filing metadata
- accession: 0001193125-26-216744
- form_type: 8-K
- ticker: EIKN
- cik: 0001861123
- company_name: Eikon Therapeutics, Inc.
- filed_at: 2026-05-11T20:05:32+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/0001193125-26-216744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/eikn-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216744
- JSON: https://secwatch.observer/filing/0001193125-26-216744.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216744.txt

## Key facts
- Earnings Releases
  Eikon Therapeutics, Inc. reported first quarter 2026 results: net income $83.0 million.
  - Period: first quarter 2026
  - Net income: $83.0 million
  - Result: reported results
  source text: Net loss attributable to common stockholders was $83.0 million for the first quarter of 2026, as compared to $74.5 million for the prior-year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/0001193125-26-216744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.